Clinical trial
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in…
NCT03622593 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT03622593 |
|---|---|
| Title | A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema |
| Official title | A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE) |
| Acronym | RHINE |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Macular Edema |
| Intervention type | Drug, Procedure |
| Interventions | Aflibercept, Faricimab, Sham Procedure |
| Enrollment | 951 |
| Start date | Oct 9, 2018 |
| Primary completion | Oct 19, 2020 |
| Completion | May 31, 2023 |
| First posted | Aug 9, 2018 |
| Last update posted | Jul 11, 2025 |
| Countries | Argentina, Australia, Brazil, Canada, China, Czechia, Denmark, France, Germany, Hong Kong, Hungary, Italy and 12 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: